ClinicalTrials.gg
CompletedNCT01138436Updated Nov 6, 2025

A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers

A Phase 2 interventional study of MEBO Wound Ointment (MEBO) and Standard of Care in Ulcers, sponsored by Skingenix, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Skingenix, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 141 studies in Ulcer with a site in United States — 24 open to participants now, 27 under way, none of them phase 3. Ulcer · United States.

Enrollment
117th of 124
5 · median 95
Started
2010
with 4 others
Phase 2
29 of 141
2 open now
Registered
44th of 141
by date

Among the 141 studies in Ulcer with a site in United States, this one is the 117th largest by enrollment of the 124 interventional ones that give a count, is one of 5 that started in 2010, is one of 29 in phase 2, and was the 44th registered.

Ulcer

360 studies on the registry are indexed under Ulcer; 61 are open to participants now.

Browse Ulcer studies →

Open to participants now

24 of the 141 studies in Ulcer with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Ulcer with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, randomized, controlled, two-center pilot study designed to assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC (7 subjects per treatment arm).

Read the detailed description

To assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC (7 subjects per treatment arm).

03

Conditions studied

  • Ulcers

Browse trials for

Keywords

  • Venous Leg Ulcers, VLU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age.
  2. Able and willing to provide .
  3. Able and willing to comply with protocol visits and procedures.
  4. A full-thickness VLU that has been open continuously for ≥4 weeks and ≤1 year.

Exclusion criteria

Exclusion Criteria:

  1. Ulcer of a non-venous hypertensive pathophysiology.
  2. Known or suspected allergy to any of the components of MEBO.
  3. on target ulcer limb.
  4. Received another device or drug within 30 days of enrollment.
  5. Non-compliance in the screening or run-in period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    MEBO Wound Ointment (MEBO)

    Topical application once a day

    Drug: MEBO Wound Ointment (MEBO)

  • Active comparator
    Standard of Care

    Application of Profore multilayer compression bandage system

    Procedure: Standard of Care

Interventions

  • DrugMEBO Wound Ointment (MEBO)

    Topical application once a day

    Also known as: MEBO

  • ProcedureStandard of Care

    Application of Profore multilayer compression bandage system

06

What researchers measure

Primary outcomes

  1. Incidence of complete healing of the target ulcer within the 8-week treatment period.

    Time frame: 8 week treatment period

07

Study locations

2 sites
  • Center for Clinical Research, Inc.
    Castro Valley, California 94546, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2010
First posted
Jun 7, 2010
Start
Nov 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results delay requested
Jul 19, 2013
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01138436
Lead sponsor
Skingenix, Inc.
Responsible party
Sponsor
First posted
Jun 7, 2010
Start date
Nov 2010
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Nov 6, 2025

Study contacts

Robert Kirsner, MD, PhD
study chair · University of Miami

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion